Bryant  Fong net worth and biography

Bryant Fong Biography and Net Worth

Director of ADMA Biologics
Mr. Fong, who became a director of the Company in May 2012 and is currently a member of the Company’s Governance and Nominations Committee and Chairman of the Audit Committee and the Compensation Committee, has over 25 years of experience in the life sciences industry. Mr. Fong is a founding Managing Director and General Partner at Biomark Capital Fund, a life sciences private equity firm formed in 2013 (“Biomark Capital”). Prior to Biomark Capital, Mr. Fong was a Managing Director and General Partner of Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s most notable investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Ceptaris Therapeutics, Ferrokin Biosciences, and WaveTec Vision. Prior to joining Burrill & Company, Mr. Fong held positions as a research scientist with two early stage biotechnology companies located in the San Francisco Bay area. Mr. Fong currently serves on the boards of directors of a number of private life science companies. Mr. Fong earned his B.S. with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley. He was nominated by Biomark Capital to serve on the Board because of his extensive experience in the biotechnology industry.

What is Bryant Fong's net worth?

The estimated net worth of Bryant Fong is at least $1.27 million as of August 22nd, 2023. Mr. Fong owns 59,901 shares of ADMA Biologics stock worth more than $1,268,703 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Fong may own. Learn More about Bryant Fong's net worth.

How do I contact Bryant Fong?

The corporate mailing address for Mr. Fong and other ADMA Biologics executives is 465 STATE ROUTE 17, RAMSEY NJ, 07446. ADMA Biologics can also be reached via phone at (201) 478-5552 and via email at [email protected]. Learn More on Bryant Fong's contact information.

Has Bryant Fong been buying or selling shares of ADMA Biologics?

Bryant Fong has not been actively trading shares of ADMA Biologics during the last ninety days. Most recently, Bryant Fong sold 1,433,304 shares of the business's stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $3.87, for a transaction totalling $5,546,886.48. Following the completion of the sale, the director now directly owns 59,901 shares of the company's stock, valued at $231,816.87. Learn More on Bryant Fong's trading history.

Who are ADMA Biologics' active insiders?

ADMA Biologics' insider roster includes Steve Elms (Director), Bryant Fong (Director), Adam Grossman (Co-Founder, President, CEO & Director), Jerrold Grossman (Director), Lawrence Guiheen (Director), Young Kwon (Director), and Brian Lenz (CFO). Learn More on ADMA Biologics' active insiders.

Are insiders buying or selling shares of ADMA Biologics?

During the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 1,221,795 shares worth more than $13,540,539.83. The most recent insider tranaction occured on November, 22nd when CFO Brad L Tade sold 15,000 shares worth more than $317,250.00. Insiders at ADMA Biologics own 3.7% of the company. Learn More about insider trades at ADMA Biologics.

Information on this page was last updated on 11/22/2024.

Bryant Fong Insider Trading History at ADMA Biologics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2023Sell1,433,304$3.87$5,546,886.4859,901View SEC Filing Icon  
See Full Table

Bryant Fong Buying and Selling Activity at ADMA Biologics

This chart shows Bryant Fong's buying and selling at ADMA Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ADMA Biologics Company Overview

ADMA Biologics logo
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Read More

Today's Range

Now: $21.18
Low: $20.88
High: $21.48

50 Day Range

MA: $18.86
Low: $15.62
High: $22.62

2 Week Range

Now: $21.18
Low: $3.60
High: $23.64

Volume

2,107,830 shs

Average Volume

3,886,240 shs

Market Capitalization

$5.01 billion

P/E Ratio

75.64

Dividend Yield

N/A

Beta

0.64